Should you buy Salesforce shares after issuing disappointing FQ4 guidance?

Should you buy Salesforce shares after issuing disappointing FQ4 guidance?

On Tuesday, Salesforce.com Inc. (NYSE:CRM) shares declined by nearly 4% ahead of its FQ3 results. The stock sank further by more than 6% despite beating analyst expectations on revenue and earnings. Investors seem to have put more emphasis on its underwhelming FQ4 guidance. Salesforce posted FQ3 non-GAAP earnings per share of $1.27, smashing the average
The post Should you buy Salesforce shares after issuing disappointing FQ4 guidance? appeared first on Invezz.